Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 45

Sort by

Sort Order Select

Journal Articles

Severe COVID-19 Infection in Patients with Chronic Lymphocytic Leukemia or Indolent B-Cell Non-Hodgkin Lymphoma Who Received Pre-Exposure Prophylaxis with Tixagevimab and Cilgavimab in Italy: Preliminary Results of the Observational Study By the Gimema Working Party on Chronic Lymphoproliferative Disorders and By the Fondazione Italiana Linfomi

Blood (2024) 144 (Supplement 1): 1872.

https://doi.org/10.1182/blood-2024-199014

Published: 2024

Journal Articles

TP53 , CD36 Mutations and CDKN2A Loss Predict Poor Outcome in Mantle Cell Lymphoma: Molecular Analysis of the FIL V-Rbac Phase 2 Trial

Blood (2024) 144 (Supplement 1): 1577.

https://doi.org/10.1182/blood-2024-198076

Published: 2024

Journal Articles

Pet-2 Positive during Frontline Therapy: An Early Unfavorable Predictor for Subsequent Salvage High-Dose Chemotherapy (HD-CT) and Autologous Stem Cell Transplant in Relapsed or Refractory Classical Hodgkin Lymphoma

Blood (2023) 142 (Supplement 1): 6179.

https://doi.org/10.1182/blood-2023-173085

Published: 2023

Journal Articles

Results of an Italian Retrospective Clinical Experience on Mediastinal Gray Zone Lymphoma

Blood (2023) 142 (Supplement 1): 4503.

https://doi.org/10.1182/blood-2023-180036

Published: 2023

Journal Articles

Description of a Clinical Score to Identify PMBL Patients at High Risk of Early-Failure after Rituximab Doxorubicin Back-Bone Chemoimmunotherapy. a FIL Real-World Study

Emilio Iannitto, Monica Balzarotti, Maurizio Martelli, Pier Luigi Zinzani, Alessandra Tucci, Alice Di Rocco, Federica Cavallo, Sara Usai, Anna Guidetti, Emanuele Ravano, Franceso Merli, Barbara Botto, Matteo Pelosini, Cristina Tecchio, Michele Spina, Enrico Derenzini, Silvia Finotto, Brunella Mola, Antonio Pinto, Manuela Zanni, Roberta Battistini, Stefan Hohaus, Irene Dogliotti, Guido Gini, Vittorio Ruggero Zilioli, Sonya De Lorenzo, Anna Dodero, Alessandro Broccoli, Alessandro Maggi, Clara Mannarella, Annalisa Chiarenza, Domenico Pastore, Pellegrino Musto, Caterina Stelitano, Francesco Di Raimondo, Nicola Cascavilla, Nicola Di Renzo, Marilena Salerno, Renato Scalone, Luca Nassi, Attilio Guarini, Caterina Patti, Vita Polizzi, Gabriella Amato, Giovannino Ciccone, Andrea Evangelista, Agostino La Porta, Angelo Genua, Donato Mannina, Ciro Maria Improta, Alessandro Re, Fabrizio Lo Presti, Rosalba Donatella Calogero, Maurizio Musso, Ugo Consoli

Blood (2023) 142 (Supplement 1): 986.

https://doi.org/10.1182/blood-2023-178197

Published: 2023

Journal Articles

Rituximab, Bendamustine and Cytarabine Followed By Venetoclax (V-RBAC) in High-Risk Older Patients with Mantle Cell Lymphoma: A Phase 2 Study By the Fondazione Italiana Linfomi (FIL)

Blood (2023) 142 (Supplement 1): 737.

https://doi.org/10.1182/blood-2023-179169

Published: 2023

Journal Articles

Copanlisib in Combination with Rituximab and Bendamustine for Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients: Results from the Phase II Multicenter Fil_Copa-Rb Trial from Fondazione Italiana Linfomi (FIL)

Blood (2023) 142 (Supplement 1): 1728.

https://doi.org/10.1182/blood-2023-184718

Published: 2023

Journal Articles

Lenalidomide plus rituximab for the initial treatment of frail older patients with DLBCL: the FIL_ReRi phase 2 study

Blood (2023) 142 (17): 1438–1447.

https://doi.org/10.1182/blood.2022019173

Published: 2023

Includes: Supplemental data

Journal Articles

How Age, Comorbidities and Concomitant Medications Influence Ibrutinib Management and Survival in Waldenstrom Macroglobulinemia

Blood (2022) 140 (Supplement 1): 6528–6530.

https://doi.org/10.1182/blood-2022-169776

Published: 2022

Journal Articles

Frequency and Risk Factors for Venous Thromboembolism Among Patients with Multiple Myeloma or Aggressive Lymphoma: A 6-Year Single Center Retrospective Analysis

Erika Morsia, Elena Torre, Francesca Marrara, Sonia Morè, Mauro Petrini, Valentina Maria Manieri, Laura Gurgoglione, Guido Gini, Massimo Offidani, Attilio Olivieri, Serena Rupoli

Blood (2022) 140 (Supplement 1): 11375.

https://doi.org/10.1182/blood-2022-163790

Published: 2022

Journal Articles

Lenalidomide and Rituximab (ReRi) As Front-Line Chemo-Free Therapy for Elderly Frail Patients with Diffuse Large B-Cell Lymphoma. a Phase II Study of the Fondazione Italiana Linfomi (FIL)

Blood (2021) 138 (Supplement 1): 305.

https://doi.org/10.1182/blood-2021-148380

Published: 2021

Journal Articles

Lesion Dissemination in Baseline PET/CT (D-MAX) and IPS Score Predict ABVD Treatment Outcome in PET-2 Negative Advanced-Stage Hodgkin Lymphoma Patients Enrolled in the Prospective GITIL/FIL HD0607 Trial

Blood (2021) 138 (Supplement 1): 2443.

https://doi.org/10.1182/blood-2021-152292

Published: 2021

Journal Articles

Rituximab, Bendamustine and Cytarabine Followed By Venetoclax (V-RBAC) in High-Risk Elderly Patients with Mantle Cell Lymphoma

Blood (2021) 138 (Supplement 1): 2427.

https://doi.org/10.1182/blood-2021-145421

Published: 2021

Journal Articles

Comparison between R-COMP and R-CHOP in Older Patients with Diffuse Large B-Cell Lymphoma (DLBCL): A Substudy of the Elderly Project By the Fondazione Italiana Linfomi

Blood (2021) 138 (Supplement 1): 2487.

https://doi.org/10.1182/blood-2021-150337

Published: 2021

Journal Articles

Do MYC Alterations Matter in HIV-Associated Large B Cell Lymphomas? the "Euromyc" Study (a European retrospective study)

Chiara Pagani, Chiara Rusconi, Alessia Dalla Pria, Emanuele Ravano, Philipp Schommers, Mariana Bastos-Oreiro, Luisa Verga, Guido Gini, Michele Spina, Luca Arcaini, Sara Steffanoni, Davide Dalu, Chiara Cattaneo, Fabio Facchetti, Giuseppe Rossi, Alessandra Tucci, Alessandro Re

Blood (2021) 138 (Supplement 1): 2506.

https://doi.org/10.1182/blood-2021-151149

Published: 2021

Journal Articles

Impact of Direct-Acting Antivirals on the Outcome of HIV/HCV Coinfected Patients with Non-Hodgkin Lymphomas in the Modern Anti-Retroviral Therapy Era: A Retrospective Multicenter Study of 74 Cases

Blood (2021) 138 (Supplement 1): 1434.

https://doi.org/10.1182/blood-2021-151174

Published: 2021

Journal Articles

Impact of Immunochemotherapy with R-Bendamustine or R-CHOP in the Post-Induction Management of Treatment Naïve Advanced Stage Follicular Lymphoma Patients: A Subset Analysis of the FOLL12 Trial By the Fondazione Italiana Linfomi (FIL)

Blood (2021) 138 (Supplement 1): 811.

https://doi.org/10.1182/blood-2021-148581

Published: 2021

Journal Articles

Definition and Validation of the New Elderly Prognostic Index (EPI) for Elderly Patients with Diffuse Large B-Cell Lymphoma Integrating Geriatric and Clinical Assessment: Results of the Prospective "Elderly Project" on 1353 Patients By the Fondazione Italiana Linfomi

Blood (2019) 134 (Supplement_1): 398.

https://doi.org/10.1182/blood-2019-123027

Published: 2019

Journal Articles

Lenalidomide and Rituximab (ReRi) As Front Line Chemo-Free Therapy of Elderly Frail Patients with Diffuse Large B-Cells Lymphoma. a Phase II Study of the Fondazione Italiana Linfomi (FIL)

Guido Gini, MD, Monica Tani, Alessandra Tucci, MD, Renato Bassan, MD, Filippo Ballerini, MD, Michela Sampaolo, Francesco Merli, MD, Francesca Re, Attilio Olivieri, Ombretta Annibali, Anna Marina Liberati, Carlo Visco, Annalisa Arcari, MD, Sergio Storti, MD, Alberto Fabbri, MD, Gerardo Musuraca, MD, Vittorio Ruggero Zilioli, MD, M. Christina Cox, MD PhD, Stefano Luminari, MD

Blood (2019) 134 (Supplement_1): 2880.

https://doi.org/10.1182/blood-2019-126568

Published: 2019

Journal Articles

R-CHOP Preceded By Engineered Tumor Necrosis Factor (TNF) in Patients with Relapsed or Refractory (r/r) Primary CNS Lymphoma (PCNSL): Results of Antitumor Activity, Safety and Blood-Brain Barrier (BBB) Permeabilization in the "Ingrid" Phase II Trial

Blood (2018) 132 (Supplement 1): 1687.

https://doi.org/10.1182/blood-2018-99-118507

Published: 2018

NARROW

TP53 , CD36 Mutations and CDKN2A Loss Predict Poor Outcome in Mantle Cell Lymphoma: Molecular Analysis of the FIL V-Rbac Phase 2 Trial

Pet-2 Positive during Frontline Therapy: An Early Unfavorable Predictor for Subsequent Salvage High-Dose Chemotherapy (HD-CT) and Autologous Stem Cell Transplant in Relapsed or Refractory Classical Hodgkin Lymphoma

Results of an Italian Retrospective Clinical Experience on Mediastinal Gray Zone Lymphoma

Description of a Clinical Score to Identify PMBL Patients at High Risk of Early-Failure after Rituximab Doxorubicin Back-Bone Chemoimmunotherapy. a FIL Real-World Study

Rituximab, Bendamustine and Cytarabine Followed By Venetoclax (V-RBAC) in High-Risk Older Patients with Mantle Cell Lymphoma: A Phase 2 Study By the Fondazione Italiana Linfomi (FIL)

Copanlisib in Combination with Rituximab and Bendamustine for Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients: Results from the Phase II Multicenter Fil_Copa-Rb Trial from Fondazione Italiana Linfomi (FIL)

Lenalidomide plus rituximab for the initial treatment of frail older patients with DLBCL: the FIL_ReRi phase 2 study

How Age, Comorbidities and Concomitant Medications Influence Ibrutinib Management and Survival in Waldenstrom Macroglobulinemia

Frequency and Risk Factors for Venous Thromboembolism Among Patients with Multiple Myeloma or Aggressive Lymphoma: A 6-Year Single Center Retrospective Analysis

Lenalidomide and Rituximab (ReRi) As Front-Line Chemo-Free Therapy for Elderly Frail Patients with Diffuse Large B-Cell Lymphoma. a Phase II Study of the Fondazione Italiana Linfomi (FIL)

Lesion Dissemination in Baseline PET/CT (D-MAX) and IPS Score Predict ABVD Treatment Outcome in PET-2 Negative Advanced-Stage Hodgkin Lymphoma Patients Enrolled in the Prospective GITIL/FIL HD0607 Trial

Rituximab, Bendamustine and Cytarabine Followed By Venetoclax (V-RBAC) in High-Risk Elderly Patients with Mantle Cell Lymphoma

Comparison between R-COMP and R-CHOP in Older Patients with Diffuse Large B-Cell Lymphoma (DLBCL): A Substudy of the Elderly Project By the Fondazione Italiana Linfomi

Do MYC Alterations Matter in HIV-Associated Large B Cell Lymphomas? the "Euromyc" Study (a European retrospective study)

Impact of Direct-Acting Antivirals on the Outcome of HIV/HCV Coinfected Patients with Non-Hodgkin Lymphomas in the Modern Anti-Retroviral Therapy Era: A Retrospective Multicenter Study of 74 Cases

Impact of Immunochemotherapy with R-Bendamustine or R-CHOP in the Post-Induction Management of Treatment Naïve Advanced Stage Follicular Lymphoma Patients: A Subset Analysis of the FOLL12 Trial By the Fondazione Italiana Linfomi (FIL)

Definition and Validation of the New Elderly Prognostic Index (EPI) for Elderly Patients with Diffuse Large B-Cell Lymphoma Integrating Geriatric and Clinical Assessment: Results of the Prospective "Elderly Project" on 1353 Patients By the Fondazione Italiana Linfomi

Lenalidomide and Rituximab (ReRi) As Front Line Chemo-Free Therapy of Elderly Frail Patients with Diffuse Large B-Cells Lymphoma. a Phase II Study of the Fondazione Italiana Linfomi (FIL)

R-CHOP Preceded By Engineered Tumor Necrosis Factor (TNF) in Patients with Relapsed or Refractory (r/r) Primary CNS Lymphoma (PCNSL): Results of Antitumor Activity, Safety and Blood-Brain Barrier (BBB) Permeabilization in the "Ingrid" Phase II Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only